| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 6.9MM | +65% |
| Operating Income | -4.3MM | -15% |
| Operating Expenses | 11.2MM | +21% |
| Net Income | -30.3MM | - |
| G&A | 4MM | +26% |
| Amortization | - | - |
| Interest Expense | 115K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform. The Laetose™ technology demonstrates compelling potential in reducing caloric intake and glycemic index in foods, whi
Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in CompanyNEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating across four distinct market sectors, announced today a significant investment by its Chairman of the Board, Heng Fai Ambrose Chan. In a strategic move to bolster shareholder confidence and underscore his commitment to the company’s growth. Chairman Chan acquired an additional 672,1
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, today announced that it will proceed with a 1-for-20 reverse stock split (the “Reverse Split”) of its issued and outstanding shares of common stock, par value $0.02, following authorization by its Board of Directors and majority
By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT DSS (NYSE:DSS) reported Q3 revenues of $4.2 million, down 65% from the year ago’s $11.9 million. Most of the total revenue decline was driven by a $4.4 million decline in Direct Marketing revenues as the company divested Sharing Global Services on May 4th. Direct marketing was down 89% year over year. On April 5th, Sharing was dividended
Option for Fourth Year Brings Potential Revenue to Over $15 MillionNEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that its wholly-owned subsidiary, Premier Packaging, signed a contract extension with an existing client for the next three years totaling a minimum of $12
Biotechnology Company Currently in Initial Public Offering (IPO) ProcessNEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc. (“the Company” and “Impact”) announced today that the Company filed a Current Report on Form 8-K with the Securities and Exchange Commission on November 6, 2023, disclosing that DSS BioHealth Security, Inc. (“DBH”), a subsidiary of DSS, Inc. (NYSE American: DSS), converted substantially all of its 87.5% common stock equity interest in Impact into an equivale
NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unanimous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No. 6,879,040 (the ‘040 Patent). U.S. Chief Circuit Judge Kimberly Moore, who authored the opinion, and U.S. Circuit Judges Kara Stoll and Tiffany Cunningham sat on the panel for the Federal Circuit. The CAFC appeal mounted by Nichia Corp., a Japanese electronics company, as
DSS Shareholders to Benefit from Reduction in Common Stock of Impact BiomedicalNEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that Impact BioMedical Inc. (“Impact”) filed a Current Report on Form 8-K with the Securities and Exchange Commission on November 6, 2023, disclosing that Impact effected a reverse stock split of its issued and outstanding common stock by a ratio of 1 for 55. Impact did not effectuate a reverse split of its authorized capital st
Company intends to cure the deficiency and return to compliance with NYSE American standardNEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) announced today that the Company received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003(f)(v) of the NYSE American Company Guide. The Company’s continued listi
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) ("DSS") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of the Company's wholly-owned subsidiary, Impact Biomedical (hyperlink: https://www.impactbiomedinc.com/). DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered